Genomics

Dataset Information

0

Combined Inhibition of JAK/STAT Pathway and Lysine Demethylase 1 as a Novel Therapeutic Strategy in CSF3R/CEBPA Mutant Acute Myeloid Leukemia [LSD1i ChIP-seq]

ABSTRACT: The presence of CSF3R mutations are associated with adverse outcomes in CEBPA mutant AML. Here we report that inhibitors of LSD1 reverse the mutant CEBPA-mediated differentiation blockade and exhibit synergy with JAK/STAT inhibitors.

ORGANISM(S): Mus musculus

PROVIDER: GSE138387 | GEO | 2020/07/02

REPOSITORIES: GEO

Json Xml

Similar Datasets

Transcriptomics Combined Inhibition of JAK/STAT Pathway and Lysine Demethylase 1 as a Novel Therapeutic Strategy in CSF3R/CEBPA Mutant Acute Myeloid Leukemia [RUX_GSK RNA-seq]
2020-07-02 | GSE138386 | GEO
Transcriptomics Combined Inhibition of JAK/STAT Pathway and Lysine Demethylase 1 as a Novel Therapeutic Strategy in CSF3R/CEBPA Mutant Acute Myeloid Leukemia [LSD1i RNA-seq]
2020-07-02 | GSE138384 | GEO
Transcriptomics CEBPA Dysfunction Intiates CSF3R Mutant Acute Myeloid Leukemia Through Disruption of Myeloid Lineage Enhancers (Microarray)
2019-12-02 | GSE122161 | GEO
Genomics CEBPA Dysfunction Intiates CSF3R Mutant Acute Myeloid Leukemia Through Disruption of Myeloid Lineage Enhancers (ChIP-seq)
2019-12-02 | GSE122162 | GEO
Transcriptomics CEBPA Dysfunction Intiates CSF3R Mutant Acute Myeloid Leukemia Through Disruption of Myeloid Lineage Enhancers (RNA-seq - simultaneous)
2019-12-02 | GSE122164 | GEO
Transcriptomics CEBPA Dysfunction Intiates CSF3R Mutant Acute Myeloid Leukemia Through Disruption of Myeloid Lineage Enhancers (RNA-seq - orders)
2019-12-02 | GSE122163 | GEO
Genomics Combined Inhibition of JAK/STAT Pathway and Lysine Demethylase 1 as a Novel Therapeutic Strategy in CSF3R/CEBPA Mutant Acute Myeloid Leukemia
| PRJNA575722 | ENA
Unknown Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
| S-EPMC7306806 | biostudies-literature
Genomics Combined Inhibition of JAK/STAT Pathway and Lysine Demethylase 1 as a Novel Therapeutic Strategy in CSF3R/CEBPA Mutant Acute Myeloid Leukemia [LSD1i RNA-seq]
| PRJNA575724 | ENA
Genomics Combined Inhibition of JAK/STAT Pathway and Lysine Demethylase 1 as a Novel Therapeutic Strategy in CSF3R/CEBPA Mutant Acute Myeloid Leukemia [RUX_GSK RNA-seq]
| PRJNA575725 | ENA